Cervical Cancer Prevention: Liquid-Based Cytology and hr-HPV Co-testing Remain the Most Effective Cervical Cancer Screening Method

Insights

In our opinion, the best evidence still supports screening with Pap and hr-HPV together to provide the best protection against cervical cancer for women ages 30 to 65.

You Can Protect Women’s Access to Co-Testing (Pap and HPV together) for Cervical Cancer

Action

USPSTF Considering Changes to Cervical Cancer Screening Guidelines That May Increase Risk of a Missed Diagnosis